Crystal S. Denlinger, MD
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497
Colorectal Cancer Treatment at Fox Chase Cancer Center
(Mar 15, 2013)
(Jun 7, 2010)
Dr. Denlinger talks about chemotherapy side effects, WHYY FM, 1/27/2009
Co-Site Director, Temple University
Internal Medicine Residency and Student Program at Fox Chase
Meet other members of the
gastrointestinal cancer treatment team
American Board of Internal Medicine;
I have wanted to be a doctor for as long as I can remember. My decision to become an oncologist came during my teenage years, when my family became one of the many families dealing with cancer. During medical school and residency, I was drawn to the oncology patients as each person's fight against their cancer was unique, uplifting, and inspiring.
I have known many people who had been treated at Fox Chase, even before I joined the staff. All have been quick to share their positive experiences with me, including my family's own experience. That is part of the reason I chose to do my fellowship here. After completing my fellowship at Fox Chase Cancer Center in 2007, I knew this was where I wanted to practice. The relationships between physician and patient that develop during the treatment of cancer are very special, and as a medical oncologist, I am privileged to be a part of these wonderful therapeutic relationships.
While the thought of curing cancer is a lofty goal, I knew my best opportunity to become involved in cutting-edge research would lie at Fox Chase. The unique environment allows everyone to work toward a common goal without competing for individual recognition. It is a very supportive, collegial hospital in which to work. At Fox Chase, I have the ability to be involved in large clinical trials that often change the standard of care. With our amazing pool of resources, we help develop Phase I trials that have the potential to identify the next promising drug on the horizon.
Community outreach and survivorship are other interests of mine. As a physician, it's important to me to help educate the local community about cancer prevention, early detection, screening tools, coping with cancer and the latest treatment methods. For those patients completing their cancer treatment, the integration of their cancer follow-up into their health care plan is important. Ensuring that patients are educated about necessary follow-up and screening for all health-related issues is key to surviving a cancer diagnosis.
People often ask me what I do for a living. They are always surprised to hear how much I love my job. I am intimately involved in my patients' lives and find it extremely satisfying to find a cure for many patients. For my patients with metastatic disease, which is close to my heart, I am able to have a positive impact as well. Whether this means improving their quality of life or extending their number of years on this earth, it is most gratifying to be able to help my patients.
New Jersey Medical School, University of Medicine & Dentistry of New Jersey, Newark, N.J., 2001
Internal Medicine, Mount Sinai Medical Center, New York, N.Y.
Hematology-Oncology, Fox Chase Cancer Center and Temple University Hospital, Phila., Pa., Chief Fellow
Gastrointestinal cancers; Cancer Survivorship; Drug Development
Dr. Denlinger on My NCBI
- Denlinger CS, Blanchard R, Xu L, Bernaards C, Litwin S, Spittle C, Berg DJ, McLaughlin S, Redlinger M, Dorr A, Hambleton J, Holden S, Kearns A, Kenkare-Mitra S, Lum B, Meropol NJ, O’Dwyer PJ. Pharmacokinetic and pharmacogenetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmocology, Dec;65(1):97-105, 2009. Epub 2009 May 5. PMID: 2746259,NIHMS 110194. Pub Med
- Denlinger CS, Barsevick AM. The challenges of colorectal cancer survivorship. Journal of the National Comprehensive Cancer Network, 7(8): 883-894, 2009. PMID: 19755048. Pub Med
- Denlinger CS, Engstrom PF. Colorectal cancer survivorship: movement matters. Cancer Prevention Research, 4(4):502-11, Apr, 2011. Epub April 3, 2011. PMID: 21464030. Pub Med
- Dotan E, Browner I, Hurria A, Denlinger C. Challenges in the Management of Older Patients With Colon Cancer. Journal of the National Comprehensive Cancer Network, 10(2): p. 213-224, 2012. PMID: 22308516. Pub Med
- Ligibel JA and Denlinger CS. New NCCN Guidelines(R) for survivorship care. Journal of the National Comprehensive Cancer Network, 11(5 Suppl): 640-644, 2013. Pub Med
- Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ. A phase II trial of bortezomib in patients with advanced biliary tract cancers. Clinical Colorectal Cancer 13(2): 81-86, 2014 .Epub ahead of print Jan 4 2014. PMID 24512954. Pub Med
- Denlinger CS and Ligibel J. A Work In Progress: Developing the new NCCN Survivorship Guidelines. Journal of the National Comprehensive Cancer Network, 12(1): 1-4, 2014. PMID: 24453287. Pub Med
- Dotan E, Devarajan K, D’Silva AJ, Beck A, Kloth DD, Cohen SJ, Denlinger C. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clinical Colorectal Cancer 2014 Sept; 13(3): 192-198. Epub ahead of print Jun 26 2014. PMID: 25074246. Pub Med
- Morgan MA, Denlinger CS. Survivorship: tools for transitioning patients with cancer. Journal of the National Comprehensive Cancer Network. 2014 Dec;12(12):1681-1687. PMID:25505209. Pub Med
- Shah M and Denlinger CS. Optimal post-treatment surveillance in cancer survivors: is more really better? Oncology 2015 29(4): 230-240. PMID: 25952485. Pub Med
- Vijayvergia N and Denlinger CS. Lifestyle factors in Cancer Survivorship: Where we are and where we are headed. Journal of Personalized Medicine. 2015 5(3): 243-263. Pub Med
- Vijayvergia N, Shah PC, Denlinger CS. Survivorship in non-small cell lung cancer: challenges faced and steps forward. Journal of the National Comprehensive Cancer Network. 2015 Sep;13(9):1151-61. PMID: 26358799. Pub Med